TMZ, a chemotherapy drug that is sometimes used for glioblastoma and astrocytoma brain tumours, should usually be taken post radiotherapy for six cycles, usually over six months, but some patients have told the BBC they received it for many years.
The review warned there may be many more affected patients, with 83 receiving extended TMZ treatment between 2017 and 2023.
Overall, the RCP examined 20 cases of care under Brown, though the number of patients affected is higher – including those who have since died.
Working to strict definitions of harm, the review team concluded six patients had suffered severe harm, five moderate harm and eight low levels of harm. In the final case, the review team could not reach a judgement on moderate or severe harm.
Among other recommendations, the RCP said that any wider review of patients who received the treatment and have since died should be discussed with the Department of Health and Social Care.
“There is a large cohort of deceased patients who have received this non-standard chemotherapy regime, who may potentially have come to harm,” the report said.
“To review every patient would be a significant and costly undertaking. The Trust should determine whether such a step is appropriate, and if so, discuss with the DHSC and/or NHS England how such a review would proceed.”
Source: https://www.bbc.co.uk/news/articles/cmwy83q9wzpvo?at_medium=RSS&at_campaign=rss